

Evaluation and Treatment of Pain and REMS

Anthony Dekker, DO

Primary Care and Telemedicine Physician

NAVAHCS

Anthony.dekker@va.gov

30APR2016 TOMF

Disclosure

- Anthony Dekker, DO has presented numerous programs on Chronic Pain Management and Addiction Medicine. The opinions of Dr Dekker are not necessarily the opinions of the VA, the DoD, Indian Health Service or the USPHS. Dr Dekker has no conflicts to report. Dr Dekker is not representing any federal organization. Dr Dekker is a clinical professor at ATSU and George Washington University

Pain & Opioids in the US

- Discrepancies in Treatment, *JAMA Pediatr.* doi:10.1001/jamapediatrics.2015.1915
Published online September 14, 2015.
- Rising concerns of complications
- 2016 CDC and HHS Guidelines
- Chronic Non-Malignant Pain Evaluation and Care evaluations
- Increasing complications from misuse and diversion
- Provider and Pharmacy concerns
- Patient and Community expectations
- DEA investigations
- Patient perceptions of lack of care

NASPER


2016 TOMF

4

National All Schedules Prescription Electronic Reporting Act

- Signed into law by President Bush August 2005
- Point of care reference to all controlled substances prescribed to a given patient
- MD PMP is to monitor patients and providers
- Treatment tool vs. Law enforcement tool?

Sale of Opioids 1997-2002



Source: 2002 National Survey on Drug Use and Health (NSDUH).

Results from the 2002 National Survey on Drug Use and Health: National Findings. Department of Health and Human Services

Risk Assessment Tools: Examples⁵

Tool	# of items	Administered
Patients considered for long-term opioid therapy:		
ORT Opioid Risk Tool	5	By patient
SOAPP® Screener & Opioid Assessment for Patients w/ Pain	24, 14, & 5	By patient
DIRE Diagnosis, Intractability, Risk, & Efficacy Score	7	By clinician
Characterize misuse once opioid treatments begins:		
PMQ Pain Medication Questionnaire	26	By patient
COMM Current Opioid Misuse Measure	17	By patient
PDUQ Prescription Drug Use Questionnaire	40	By clinician
Not specific to pain populations:		
CAGE-AID Cut Down, Annoyed, Guilty, Eye-Opener Tool, Adjusted to Include Drugs	4	By clinician
RAFFT Relax, Alone, Friends, Family, Trouble	5	By patient
DAST Drug Abuse Screening Test	28	By patient
SBIRT Screening, Brief Intervention, & Referral to Treatment*	Varies	By clinician

Chronic Non-Malignant Pain (CNMP)

2016 TOMF

- Osteoarthritis
- Low back pain and hip pain
- Myofascial pain
- Vaso-Occlusive Disease
- Fibromyalgia
- Headaches (e.g., migraine, tension-type, cluster)
- “Central pain” (e.g., spinal cord injury, CVA, MS)
- Chronic abdominal pain (e.g., chronic pancreatitis, chronic PUD, IBS)
- CRPS, Types I and II
- Phantom limb pain
- Peripheral neuropathy
- Neuralgia (e.g., post-herpetic, trigeminal)

Treatment Goals

- In malignant pain we treat to goal
- In chronic non malignant pain we treat to function

Treatment goals in managing CNMP

2016 TOMF

8

- Improve patient functioning
- Identify, eliminate/reduce pain reinforcers
- Increase physical activity
- Decrease or eliminate illegal or complicating drug use

The goal is NOT pain eradication!

CNMP:

The clinical challenge

2016 TOMF

9

- Be aware of the “Heart Sink” patient.
- Be aware of the borderline patient
- Remain within your area of expertise.
- Stay grounded in your role.
 - FIRST....Do no harm
 - THEN.....
 - Cure sometimes
 - Comfort always

Non-pharmacologic treatments for CNMP

2016 TOMF

10

- ✓ Physical therapy – conditioning, thermal therapies
- ✓ Pain Psychology – relaxation / counseling / expectations orientation
- ✓ Traditional Indian Medicine
- ✓ Massage therapy
- ✓ Osteopathic and Chiropractic Manipulative Therapies
- ✓ Spinal manipulation
- ✓ Acupuncture, with and without stimulation
- ✓ TENS units and micro-current therapies
- ✓ Nerve ablations and blocks
- ✓ Pain management group
- ✓ Yoga and meditation

Non-opioid medications for CNMP

- Acetaminophen
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Tricyclics
- Anti-depressants/anxiolytics
- Anti-convulsants
- Muscle relaxants
- Topical preparations—e.g. anesthetics, aromatics
- Others (e.g., tramadol)

Non-opioid medications (cont.)

- **Non-steroidal anti inflammatory drugs (NSAIDS) Inhibit prostaglandin synthesis:**
 - Works on Cyclo-Oxygenase (COX) COX-1 and COX-2
 - ↓ pain-minutes to hours

- **COX-1:**

Aspirin, Ibuprofen, Naproxen, Ketoprofen, Indomethacin, Diclofenac, Piroxicam, Sulindac

Non-opioid medications (cont.)

■ COX-2 Inhibitors:

- ↓ gastrointestinal effect
- Normally not present but induced during inflammation
- Celecoxib (Celebrex[®]);
- Rofecoxib (Vioxx[®]); Valdecoxib (Bextra[®])
withdrawn from market due to increased cardiovascular risk

Non-opioid medications (cont.)

■ Antidepressants:

- ↓ reuptake of serotonin & norepinephrine
- ↑ sleep
- Enhance descending pain-modeling paths
- Tricyclics —amitriptyline (Elavil[®])—most studied/most SE's and nortriptyline (Pamelor[®])
- SSRIs—not as effective
- SNRI (venlafaxine, Effexor[®]; duloxetine, Cymbalta[®])
preliminary evidence of efficacy in neuropathic pain

Non-opioid medications (cont.)

■ Antiepileptic drugs:

- ↓ neuronal excitability
- Exact mechanism is unclear
- Not due to antiepileptic activity
e.g. phenobarbital is poor analgesic
- Good for stabbing, shooting, episodic pain from neuropathic pain
- Gabapentin (Neurontin®)
- Pregabalin (Lyrica®)
- Carbamazepine (Tegretol®)
- Topiramate (Topamax®)

Non-opioid medications (cont.)

- **Other drugs:**

- **Tramadol (Ultram)**

- Mixed mu opioid agonist & NE/serotonin reuptake inhibitor
 - Seizure threshold changes
 - NM and TN (now DEA Scheduled)

- **Corticosteroids**

- ↓ inflammation, swelling

- **Baclofen**

- GABA receptor agonist
 - Used for spasticity

Indications for opioid therapy

1. Is there a **clear diagnosis**?
2. Is there **documentation** of an adequate work-up?
3. Is there **impairment of function**?
4. Has non-opioid multimodal therapy **failed**?
5. Have **contraindications** been ruled out?

Begin opioid therapy:

Document

Monitor

Avoid poly-pharmacy

Contraindications to opioid therapy

- Allergy to opioid medications ~ **relative**
- Current addiction to opioids ~ **?absolute**
- Past addiction to opioids ~ **?absolute**
- Current /past addiction, opioids never involved ~ **relative; absolute?? if cocaine, methamphetamine or other stimulants**
- Severe COPD or OSA~ **relative**
- **Concurrent Sedative hypnotics~relative**

**Pain Patient on
Opioids**

+

New Provider

2016 TOMF

19

Are chronic opioids appropriate?

YES!

Re-document:

Diagnosis

Work-up

Treatment goal

Functional status

Pain P&P ↓

Monitor Progress:

Medication counts

Function

Refill flow chart

Occasional urine
toxicology

Adjust medications

Watch for scams

UNSURE

Physical Dependence vs Addiction:

Chemical dependence
screening

Toxicology tests

Medication counts

Monitor for scams

Reassess for
appropriateness

NO

Educate patient
on need to
discontinue opioids

Emergency?

ie: overdoses

selling meds

altering Rx

NO!

Stop or quick taper
(document in chart)

OR

10-week structured taper

OR

Discontinue opioids at
end of structured taper

YES!

Discontinue opioids

Instruct patient on
withdrawal symptoms


OBOT Buprenorphine

Tell patient to go to ER
if symptoms emerge

FDA Methadone Warning

FDA ALERT [11/2006]: Death, Narcotic Overdose, and Serious Cardiac Arrhythmias

FDA has reviewed reports of death and life-threatening side effects such as slowed or stopped breathing, and dangerous changes in heart beat in patients receiving methadone. These serious side effects may occur because methadone may build up in the body to a toxic level if it is taken too often, if the amount taken is too high, or if it is taken with certain other medicines or supplements. Methadone has specific toxic effects on the heart (QT prolongation and Torsades de Pointes). Physicians prescribing methadone should be familiar with methadone's toxicities and unique pharmacologic properties. **Methadone's elimination half-life (8-59 hours) is longer than its duration of analgesic action (4-8 hours).** Methadone doses for pain should be carefully selected and slowly titrated to analgesic effect even in patients who are opioid-tolerant. Physicians should closely monitor patients when converting them from other opioids and changing the methadone dose, and thoroughly instruct patients how to take methadone. Healthcare professionals should tell patients to take no more methadone than has been prescribed without first talking to their physician.



Upper Graph Fig 2a

21




Figure 2. Trends in the US fatal medication error (FME) death rate by type of circumstance in which the FME occurs (A) and for various comparison groups (B) (January 1, 1983–December 31, 2004).

- Type 1 (*Home with “EtOH/Street”*) has increased by **3196%**
 - Steep and accelerating rate ($p < 0.001$)
- Type 2 (*Home without EtOH/Street*) and Type 3 (*Non-Home with EtOH/Street*) increased 564% and 555%, respectively
- Type 4 (*Non-Home without “EtOH/Street”*) only increased 5%

Lower Graph Fig 2b

- Type 1 has three components:
 - Fatal Medication Errors
 - Occurring at home
 - In conjunction with EtOH/Street drugs
- The 3 components graphed separately show slight increase
- Component combined (Type 1) shows steep increase by **3196%**

- In a study of teenagers who had used drugs illicitly, 6 opioids accounted for 68% of the drugs used, 79% of major outcomes, and 100% of the deaths.
- Zosel A, Bartelson BB, Bailey E, Lowenstein S, Dart R. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS®) System. *J Am Acad Child Adolesc Psychiatry*. 2013;52(2):196-204.e2. doi:10.1016/j.jaac.2012.11.014.

Newsweek


PainKillers

**Vicodin and
OxyContin:
Hot Drugs
That Offer
Relief—And
Danger**



23

2016 TOMF



Landscape of Drug* Abuse among Teens

2016 TOMF

24

Marijuana

8.6 million

Prescription Medicine

4.5 million

Cough Medicine

2.4 million

Crack/Cocaine

2.4 million

Ecstasy

1.9 million

Meth

1.9 million

LSD

1.3 million

Heroin

1.1 million

Ketamine

1 million

GHB

1 million




*Excludes ETOH

NSDUH, 2006

Past Year Perceived Need for and Effort Made to Receive Specialty Treatment among Persons Aged 12 or Older Needing But Not Receiving Treatment for Illicit Drug or Alcohol Use: 2008

2016 TOMF





“Pharming Culture”

2016 TOMF



- ✓ Today's teens are **more likely** to have abused **Rx** and **OTC drugs** than most illicit drugs
- ✓ Every day **2,500** teens 12-17 **try** a **painkiller** for the **1st** time



Concerning Trends

- **Adolescents 12-13**
- **Teen Females**
- **Young Adults 18-24**



Top Reasons for Rx & OTC Drug Misuse²⁸

2016 TOMF



- ✓ **Social** with friends
- ✓ **Legal** - Widely Available
- ✓ Easily **Accessible**
- ✓ **Affordable**: Low Cost/**Free**
- ✓ **Safe** - Prescribed
- ✓ **Non-addictive**: Medicine



Schedules of Substances

2016 TOMF

Schedule I	→	No Accepted Medical Use High Potential for Abuse/Dependency Example: LSD, Heroin
Schedule II	→	Accepted Medical Use High Potential for Abuse/Dependency Example: Morphine, Oxycodone
Schedule III	→	Accepted Medical Use Less Potential for Abuse/Dependency Example: Buprenorphine compounds
Schedule IV	→	Accepted Medical Use Low Potential for Abuse/Dependency Example: Benzodiazepines
Schedule V	→	Accepted Medical Use Low Potential for Abuse/Dependency Example: Codeine cough syrup

Prescription Requirements

2016 TOMF

In order to be legal, a prescription must:

- Be issued by a registered practitioner
- For a legitimate medical purpose
- In the usual course of professional practice

Security features are incorporated in this form. Form is green with black print. Face of form is Green in color with the words Department of Veterans Affairs throughout. On this form is an ink dot that will change color when your thumb is applied.

FULL NAME: JOHN DOE
 ADDRESS: 123 ANYWHERE
 FACILITY NAME: FLAGSTAFF AZ 86001
 ADDRESS: NAVAPCS
 ADDRESS: FLAG CSOC

INK DOT: C6112800

Please check or circle appropriate block below:

AUTH ABSENCE ≤ 96 HOURS	AUTH ABSENCE > 96 HOURS	INPATIENT	EMP	NBC	PBC	A&A OR HB	CNH	SC	OTH

Hydrocodone 5/325
 #20 twenty
 i-iii p- 860 pm

Refill: 1 2 3 4 5 Nonrefill

Another brand, equal in quality, of the same basic drug may be dispensed, UNLESS checked. ☐

Label with medicine NAME, STRENGTH and QUANTITY unless checked. ☐

PROVIDER SIGNATURE: [Signature] DEAVA NUMBER: F05072325 DATE: 4/4/16

PRINT NAME: A Dekker CONTACT INFO: [Redacted]

VA FORM 10-2577F MAR 2011 SECURITY PRESCRIPTION FORM

Anthony Dekker, DO
 Northern Arizona Veterans Administration
 602-762-1308

21 CFR §1306.04(a)

Prescription Requirements

2016 TOMF

- DEA does not define nor regulate medical practice standards. State Medical Boards do.
- There are no federal limits on the quantity of controlled substances that may be prescribed. Be careful.
- Corresponding responsibility for proper prescribing & dispensing rests with the pharmacist who fills the prescription.

Medical issues in opioid prescribing

■ Potential benefits

- Analgesia
- Function
- Quality of life
- Lower costs

■ Potential risks

- Toxicity
- Functional impairment
- Physical dependence
- Addiction
- Hyperalgesia
- Overdose

Review of opioid efficacy (cont.)

2016 TOME

33

● In long-term studies:

- Usually observational – non randomized / poorly controlled
- Treatment durations ≤ 6 years.
- Patients usually attain satisfactory analgesia with moderate non-escalating doses (≤ 195 mg now reduced to 100mg morphine/d), often accompanied by an improvement in function, with minimal risk of addiction.

● The question of whether benefits can be maintained over years rather than months remains unanswered.

- Ballantyne JC: Southern Med J 2006; 99(11):1245-1255

Conclusions as to opioid efficacy

- Opioids are an essential treatment for some patients with CNMP.
 - They are rarely sufficient
 - They almost never provide total lasting relief
 - They ultimately fail for many
 - They pose some hazards to patients and society
- It is not possible to accurately predict who will be helped – but those with contraindications are at high risk

Desirable patient characteristics:

- No substance abuse disorder
- Reliable
- History of good medical compliance
- Willing to do their part to recover
- Recognizes that opioids are only a partial solution
- Good support (no substance abusers in the home)

If prescribing opioids:

- Establish treatment goals, such as:
 - Functional improvement
 - Work
 - Play
 - Socialization
 - Affective normalization
 - Pain ***reduction*** (versus pain ***relief***)

Formulate a treatment plan:

- Goals
 - Function
 - What should the person do anatomically?
 - Quality of life
 - Pain
 - Affect?
- Opioids or not
- Other treatment components

Practical suggestions:

2016 TOMF

38

- Have realistic expectations
- Treat the entire patient, holistic care
- Select appropriate patients
 - Screen for contraindications!
 - ***Be comfortable screening for Substance Use***
 - If pain does not result primarily from activity in the nociceptive system, it will not be eliminated by
 - Opioids / Spinal fusion / Epidural steroid injections / Antidepressants / NSAIDs

Conclusions as to opioid efficacy

- A trial (1-2 mo±) generally is safe
- (IF contraindications are ruled out)
- People who expect to take opioids and lie around the house while they get well, won't.
 - Push functional restoration, exercises
 - Lifestyle changes and weight loss
 - Make increased drugs contingent on increased activity

Kratom

- Illegal in Thailand
- Mu receptor agonist and a stimulant
- Currently legal in the US
- Over 50% of the toxicology of a major lab screening patients with addictions were positive. Only two labs testing as of January 2013.

2016 TOMF



Mitragyna Speciosa

- Used in:
 - Malaysia
 - Thailand
 - Indonesia
- Local names:
 - Ithang
 - Biak Biak
 - Ketum
 - Kakuam

Kratom Pharmacology

- Mitragynine
- Structurally similar to some hallucinogens
- No hallucinogenic activity or effects
- Acts on opioid receptors

Kratom & Opioid Treatment

- Currently used for heroin and methadone dependence in some countries
 - New Zealand
 - Thailand
- Used in detox to manage withdrawal symptoms from opioids



Kratom

- Seems to be a stimulant in lower doses
 - Mitragynine
- Seems to be sedative in higher doses
 - 7-hydroxymitragynine
- Often produces a mixed effect
- Onset 5 to 10 minutes
- Duration several hours

Kratom Side Effects

- Short term (immediate)
 - Dry mouth
 - Increased or decrease urination
 - Loss of appetite
 - Nausea and/or vomiting
- Side effects
 - Anorexia/weight loss
 - Depression
 - Addiction

2016 TOMF



Krokodil

- desomorphine that is home-cooked from codeine using toxic household products including paint thinner, gasoline, red phosphorus and iodine. When injected it is supposedly 8-10 times more potent than heroin, faster-acting, but shorter-lasting.



Krokodil

- Vasculitis
- Necrosis
- Infection with resistance
- Analgesia



Vasculitis, Ischemia, numb



Acetyl fentanyl

- Schedule I
- Russian Mafia
- Enhanced mu receptor affinity
- Enhancement for heroin when cut
- Philadelphia and Pittsburgh had over 50 deaths in 2013
- DEA believes that 10% of all heroin deaths are related to illegal fentanyl

IDU for several medications

